Oral co-supplementation of curcumin, quercetin and vitamin D3 as adjuvant therapy for mild to moderate symptoms of COVID-19 -Results from an open-label, pilot randomized controlled trial
Khan et al., Frontiers in Pharmacology
RCT 50 COVID+ outpatients in Pakistan, 25 treated with curcumin, quercetin, and vitamin D, showing significantly faster viral clearance, significantly improved CRP, and faster resolution of acute symptoms (p=0.154). Only the abstract is currently available. 168mg curcumin, 260mg quercetin and 360IU cholecalciferol.
risk of no recovery, 33.3% lower, RR 0.67, p = 0.15, treatment 10 of 25 (40.0%), control 15 of 25 (60.0%), NNT 5.0.
|
relative CRP reduction, 39.1% better, RR 0.61, p = 0.006, treatment 25, control 25.
|
risk of no viral clearance, 50.0% lower, RR 0.50, p = 0.009, treatment 10 of 25 (40.0%), control 20 of 25 (80.0%), NNT 2.5.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Khan et al., 5/1/2022, Randomized Controlled Trial, Pakistan, South Asia, peer-reviewed, 7 authors, this trial uses multiple treatments in the treatment arm (combined with curcumin and quercetin) - results of individual treatments may vary.